Genetic polymorphisms in matrix metalloproteinases (<scp>MMPs</scp>) and tissue inhibitors of <scp>MPs</scp> (<scp>TIMPs</scp>), and bladder cancer susceptibility

Wieczorek, Edyta; Reszka, Edyta; Jabłonowski, Zbigniew; Jabłońska, Ewa; Król, Magdalena Beata; Grzegorczyk, Adam; Gromadzińska, Jolanta; Sosnowski, Marek; Wąsowicz, Wojciech

doi:10.1111/bju.12230

Cited by 41 publications

(48 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They concluded that the combined genotype carrying MMP2 rs243865 allele T with MMP9 rs3918242 allele T was found to increase bladder cancer risk. 15 These results are the opposite to the previously mentioned Asian based metaanalysis. 14 According to the db SNP and HapMap data on rs243865 frequency in genetically different populations, the C allele is more common in Caucasian populations.…”

Section: Discussionmentioning

confidence: 69%

Matrix metalloproteinases polymorphisms as baseline risk predictors in malignant pleural mesothelioma

Štrbac¹,

Goričar²,

Dolžan³

et al. 2018

Radiology and Oncology

View full text Add to dashboard Cite

Patients and methods. The study included 236 patients and 161 healthy blood donors as the control group. Ten different polymorphisms in three MMP genes were genotyped using a fluorescence-based competitive allele-specific assay (KASPar): MMP2 rs243865, rs243849 and rs7201, MMP9 rs17576, rs17577, rs2250889 and rs20544, and MMP14 rs1042703, rs1042704 and rs743257. In statistical analyses continuous variables were described using median and range (25%-75%), while frequencies were used to describe categorical variables. Deviation from the Hardy-Weinberg equilibrium (HWE) was assessed using the standard chi-square test. The additive and dominant genetic models were used in statistical analyses. The association of genetic polymorphism with MM risk were examined by logistic regression to calculate odds ratios (ORs) and their 95% confidence intervals (CIs).Results. Carriers of at least one polymorphic MMP2 rs243865 allele tended to have a decreased risk for MM (OR = 0.66, 95% CI = 0.44-1.00; P = 0.050). The association was more pronounced in patients with known asbestos exposure: carriers of at least one polymorphic allele had significantly lower MM risk (OR = 0.55, 95% CI = 0.35-0.86; P = 0.009).None of the other tested polymorphisms showed association with the risk of malignant pleural mesothelioma.Conclusions. The MMP2 rs243865 polymorphism may have a protective role in malignant pleural mesothelioma development. This finding is even more evident in patients exposed to asbestos, implying a strong gene-environment interaction.

show abstract

Section: Discussionmentioning

confidence: 69%

Matrix metalloproteinases polymorphisms as baseline risk predictors in malignant pleural mesothelioma

Štrbac¹,

Goričar²,

Dolžan³

et al. 2018

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

“…A previous study conducted transient transfections and DNA-protein interaction assays, and found that the T allele of MMP9 -1562 C>T had higher promoter activity compared with the C allele due to the binding of a transcriptional repressor (Zhang et al, 1999). Several previous studies found that the MMP9 -1562 C>T polymorphism was associated with an increased risk of lung and bladder cancer and ESCC (Vairaktaris et al, 2008;Lei et al, 2009;Wieczorek et al, 2013). Lei et al (2009) reported a meta-analysis of eight case-control studies, and discovered that the MMP9 -1562 C>T polymorphism was associated with lung cancer risk.…”

Section: Discussionmentioning

confidence: 99%

“…Lei et al (2009) reported a meta-analysis of eight case-control studies, and discovered that the MMP9 -1562 C>T polymorphism was associated with lung cancer risk. Wieczorek et al (2013) reported that the MMP9-1562 T allele was linked with increased bladder cancer risk. One study reported that the MMP9-1562 C>T polymorphism was associated with increased risk of ESCC, and conversely, another report demonstrated no association (Zhou et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

Matrix metalloproteinase variants associated with risk and clinical outcome of esophageal cancer

Zhang

2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We conducted a case-control study to investigate the role of matrix metalloproteinase (MMP) 2, MMP3, and MMP9 single nucleotide polymorphisms on susceptibility to esophageal squamous cell carcinoma (ESCC) in a Chinese population, and their association with environmental factors. A total of 226 patients with ESCC, and 226 age-and gender-matched healthy controls were enrolled in this study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis was carried out on MMP2 -1306 C>T (rs243865), MMP3 -1171 5A>6A (rs3025058), and MMP9 -1562 C>T (rs3918242) genotypes. Unconditional regression analysis showed that individuals carrying the MMP2 -1306 TT genotype had a decreased incidence of ESCC compared to those with the CC genotype [odds ratio (OR) = 0.32; 95% confidence interval (CI), 0.10-0.89, P value = 0.02]. Moreover, MMP9 -1562 CC carriers were associated with an increased ESCC risk compared to those with the TT genotype (OR = 2.71; 95%CI, 1.04-7.87, P value = 0.02). In the Cox proportional hazards model, after adjusting for potential confounding factors, patients carrying the MMP9 -1562 CC genotype had a significantly increased risk of death from ESCC (hazard ratio = 2.97; 95%CI, 1.25-6.87, P value = 0.005). 4617Matrix metalloproteinases and esophageal cancer ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 4616-4624 (2015) In conclusion, this study showed that the MMP2 -1306 TT and MMP9 -1562 CC genotypes were associated with increased ESCC, and patients carrying the MMP9 -1562 CC genotype had a significantly increased risk of death from ESCC.

show abstract

“…We also found only one Chinese article in the WanFang database. As a result, 12 case-control articles were included in our meta-analysis: (Hirata et al, 2004;Zhong et al, 2005;Kader et al, 2006;Albayrak et al, 2007;Piccoli et al, 2007;Tasci et al, 2008;Tsuchiya et al, 2009;Srivastava et al, 2010aSrivastava et al, , 2010bWieczorek et al, 2013Wieczorek et al, , 2014Srivastava et al, 2013a) (Fig. 1).…”

Section: Eligible Studiesmentioning

confidence: 99%

“…A quantitative synthesis to accumulate data from different studies is needed to provide better evidence on these associations. Here, in this report, we performed a meta-analysis of 12 publications to estimate the effect of eight polymorphisms: MMP1 -1607 1G/2G (Hirata et al, 2004;Kader et al, 2006;Albayrak et al, 2007;Piccoli et al, 2007;Tasci et al, 2008;Tsuchiya et al, 2009;Srivastava et al, 2010a;Wieczorek et al, 2013), MMP2 -1306 C/T (Zhong et al, 2005;Kader et al, 2006;Srivastava et al, 2013a;Wieczorek et al, 2013), MMP3 (45E/K) G/A (Kader et al, 2006;Srivastava et al, 2010b), MMP7 -181 A/G (Srivastava et al, 2010a;Wieczorek et al, 2014), MMP9 -1562 C/T (Zhong et al, 2005;Kader et al, 2006;Wieczorek et al, 2013), MMP9 (279R/Q) A/G (Kader et al, 2006;Tasci et al, 2008;Srivastava et al, 2010b), and MMP9 (574R/P) T/C (Kader et al, 2006;Srivastava et al, 2010b), MMP9 (668Q/R) A/G (Kader et al, 2006;Srivastava et al, 2010b) on urinary cancer risk.…”

Section: Introductionmentioning

confidence: 99%

MMP1, 2, 3, 7, and 9 Gene Polymorphisms and Urinary Cancer Risk: A Meta-Analysis

Liu

Zuo

et al. 2015

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

Background: The matrix metalloproteinases (MMPs) are a family of highly conserved, metal-dependent proteolytic enzymes that play an important role in tumor invasion and metastasis. Many studies have been carried out on the association between polymorphisms in the MMP1, MMP2, MMP3, MMP7, and MMP9 genes and urinary cancer risk. However, the data from these published studies are conflicting and have low statistical power. Methods: In this study, we performed a meta-analysis of 12 different publications from the PubMed and WanFang databases, published up to May 2015, to better assess the purported associations. Odds ratios (OR) and 95% confidence intervals (CI) were determined to reveal association strengths. Results: Some significant associations were found. For the MMP1 -1607 1G/2G polymorphism, a negative association was identified for the 2G allele in bladder cancer (2G2G+2G1G vs. 1G1G: OR = 0.57, 95% CI = 0.36-0.93, p heterogeneity = 0.001) and renal cell carcinoma (2G1G vs. 1G1G: OR = 0.57, 95% CI = 0.39-0.82, p heterogeneity = 0.567). For the MMP2 -1306 C/T polymorphism, there was a negative association with the T allele for bladder cancer in the Asian population (TT+TC vs. CC: OR = 0.41, 95% CI = 0.18-0.94, p heterogeneity = 0.195). For the MMP7 -181 A/G polymorphism, a decreased bladder cancer risk was found (G-allele vs. A-allele: OR = 0.81, 95% CI = 0.66-0.98, p heterogeneity = 0.325). Conclusion: In summary, our study showed evidence that genetic polymorphisms in MMP1 for all populations, but only in the Asian population for MMP2 and MMP7, may protect against bladder cancer risk. Future studies with larger sample sizes are warranted to further evaluate these associations in more detail.

show abstract

Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibility

Cited by 41 publications

References 53 publications

Matrix metalloproteinases polymorphisms as baseline risk predictors in malignant pleural mesothelioma

Matrix metalloproteinases polymorphisms as baseline risk predictors in malignant pleural mesothelioma

Matrix metalloproteinase variants associated with risk and clinical outcome of esophageal cancer

MMP1, 2, 3, 7, and 9 Gene Polymorphisms and Urinary Cancer Risk: A Meta-Analysis

Contact Info

Product

Resources

About